Abstract
Purpose
To evaluate whether 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) more accurately predicts the histopathologic response to neoadjuvant chemotherapy (NAC) than magnetic resonance imaging (MRI) in patients with head and neck squamous cell carcinoma (HNSCC).
Procedures
Sixteen patients with HNSCC underwent FDG-PET/CT and MRI scans before and after one cycle of NAC, followed by surgical resection. The 26 surgically resected specimens of the 16 patients were analyzed. Decreases in maximum standardized uptake value (SUVmax) or in tumor maximum size (diametermax) were calculated, and their accuracies for the prediction of histopathologic response were evaluated.
Results
In histopathologic responders (n = 7), percent decreases in SUVmax were significantly higher (P < 0.001) than in non-responders (n = 19). Applying a cut-off point of 55.5%, the histopathologic response could be predicted with a sensitivity and specificity of 86% and 95%, respectively.
Conclusion
FDG-PET/CT can predict histopathologic NAC responses with higher accuracy than MRI in HNSCC patients.
Similar content being viewed by others
References
Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955
Pignon JP, le Maître A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92:4–14
The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1324:1685–1690
Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899
Ensley JF, Jacobs JR, Weaver A et al (1984) Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811–814
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Veit-Haibach P, Luczak C, Wanke I et al (2007) TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 34:1953–1962
Nishiyama Y, Yamamoto Y, Yokoe K et al (2005) FDG PET as a procedure for detecting simultaneous tumours in head and neck cancer patients. Nucl Med Commun 26:239–244
Wartski M, Le Stanc E, Gontier E et al (2007) In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun 28:365–371
Dalsaso TA, Lowe VJ, Dunphy FR et al (2007) FDG-PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 3:1–5
Andrade RS, Heron DE, Degirmenci B et al (2006) Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65:1315–1322
Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065
Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 15:4604–4610
Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863
Kodaira T, Fuwa N, Tachibana H et al (2006) Phase study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 26:2265–2268
Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530
Metz CE (1989) Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 24:234–245
Cognetti F, Pinnarò P, Carlini P et al (1988) Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. Cancer 62:251–261
Cognetti F, Pinnarö P, Ruggeri EM et al (1989) Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 7:829–837
Al-Kourainy K, Kish J, Ensley J et al (1987) Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238
Jacobs C, Goffinet DR, Goffinet L et al (1987) Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60:1178–1183
Brun E, Kjellén E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:127–135
Clark JR, Fallon BG, Dreyfuss AI et al (1988) Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. Semin Oncol 15:35–44
Yamane T, Daimaru O, Ito S et al (2004) Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 45:1838–1842
Bjurberg M, Henriksson E, Brun E et al (2009) Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 24:327–332
Weber WA, Wieder H (2006) Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33:27–37
Srinivas SM, Dhurairaj T, Basu S et al (2009) A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 23:341–348
Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828–8834
Acknowledgments
This study was financially supported by Kasahara Fund for the promotion of cancer research.
Conflict of Interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kikuchi, M., Shinohara, S., Nakamoto, Y. et al. Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma. Mol Imaging Biol 13, 368–377 (2011). https://doi.org/10.1007/s11307-010-0364-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0364-3